Preoperative Glasgow Prognostic Score as additional independent prognostic parameter for patients with esophageal cancer after curative esophagectomy
Abstract Background Inflammation accelerates tumor growth followed by reduced survival in patients with cancer. The aim of this study was to evaluate the prognostic relevance of preoperatively increased levels of C-reactive protein (CRP) and the corresponding Glasgow Prognostic Score (GPS) on patien...
Gespeichert in:
| Veröffentlicht in: | European journal of surgical oncology 2017-02, Vol.43 (2), p.445-453 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 453 |
|---|---|
| container_issue | 2 |
| container_start_page | 445 |
| container_title | European journal of surgical oncology |
| container_volume | 43 |
| creator | Lindenmann, J Fink-Neuboeck, N Avian, A Pichler, M Habitzruther, M Maier, A Smolle-Juettner, F.M |
| description | Abstract Background Inflammation accelerates tumor growth followed by reduced survival in patients with cancer. The aim of this study was to evaluate the prognostic relevance of preoperatively increased levels of C-reactive protein (CRP) and the corresponding Glasgow Prognostic Score (GPS) on patients with esophageal carcinoma undergoing curative esophagectomy. Methods The data of 174 operated esophageal cancer patients were evaluated retrospectively. Patient's demographic and clinico-pathological data, tumor specific data, preoperative plasma levels of CRP and albumin, the corresponding GPS, overall survival (OS) and progression free survival (PFS) were assessed. Results 103 (59.2%) had adenocarcinoma and 71 (40.8%) had squamous cell carcinoma. 71 patients (43%) had elevated CRP concentrations. 118 patients (71%) had GPS 0, 41 (25%) GPS 1 and 8 (4%) GPS 2. Mean GPS was 0.3 (0–2). 5-year OS was higher in patients with normal CRP than in those with increased CRP (68% vs. 39%; p = 0.007). 5-year OS in patients with GPS 0 and GPS 1 and 2 were 65% and 31% (p = 0.001). 5-year OS for the whole cohort was 56% (1 year: 83%, 3 years: 64%). Recurrence rate was 16.1% closely associated with GPS (p = 0.002). Median follow-up was 23 months (0–118 months). In multivariate analysis GPS, lymph node involvement, T stage and tumor histology were the independent prognostic parameters (p = 0.004, |
| doi_str_mv | 10.1016/j.ejso.2016.10.015 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1839112922</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0748798316309544</els_id><sourcerecordid>1839112922</sourcerecordid><originalsourceid>FETCH-LOGICAL-c411t-9558706f171a7988de3cf6311fa9968a591bca94fbbd849fc96231ede6353c303</originalsourceid><addsrcrecordid>eNp9ksuKFDEUhoMoTjv6Ai4kSzfV5lK3gAgyjKMw4MDoOqSTUz0pqyplkpqhH8T39RTdo-DCTS6H7z_hP38Iec3ZljNev-u30KewFXjGwpbx6gnZ8EqKQvCqeUo2rCnbolGtPCMvUuoZY0o26jk5E00rVavqDfl1EyHMEE3290CvBpP24YHexLCfQsre0lsbIlCTqHHOZx8mM1A_OZgBlynT-S86m2hGyBBpFyLeskcg0Qef7yikMN-ZPaDamskiY7qVtMvp6UfA5jAeXpJnnRkSvDrt5-T7p8tvF5-L669XXy4-Xhe25DwXqqrahtUdb7hBm60Dabtact4ZperWVIrvrFFlt9u5tlSdVbWQHBzUspJWMnlO3h77ooufC6SsR58sDIOZICxJcxwT50IJgag4ojaGlCJ0eo5-NPGgOdNrHLrXaxx6jWOtYRwoenPqv-xGcH8kj_NH4P0RAHR57yHqZHFqFpyPOArtgv9__w__yO3gJ2_N8AMOkPqwRMwLfegkNNO364dY_wOvJVNVWcrfGuy1Aw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1839112922</pqid></control><display><type>article</type><title>Preoperative Glasgow Prognostic Score as additional independent prognostic parameter for patients with esophageal cancer after curative esophagectomy</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Lindenmann, J ; Fink-Neuboeck, N ; Avian, A ; Pichler, M ; Habitzruther, M ; Maier, A ; Smolle-Juettner, F.M</creator><creatorcontrib>Lindenmann, J ; Fink-Neuboeck, N ; Avian, A ; Pichler, M ; Habitzruther, M ; Maier, A ; Smolle-Juettner, F.M</creatorcontrib><description>Abstract Background Inflammation accelerates tumor growth followed by reduced survival in patients with cancer. The aim of this study was to evaluate the prognostic relevance of preoperatively increased levels of C-reactive protein (CRP) and the corresponding Glasgow Prognostic Score (GPS) on patients with esophageal carcinoma undergoing curative esophagectomy. Methods The data of 174 operated esophageal cancer patients were evaluated retrospectively. Patient's demographic and clinico-pathological data, tumor specific data, preoperative plasma levels of CRP and albumin, the corresponding GPS, overall survival (OS) and progression free survival (PFS) were assessed. Results 103 (59.2%) had adenocarcinoma and 71 (40.8%) had squamous cell carcinoma. 71 patients (43%) had elevated CRP concentrations. 118 patients (71%) had GPS 0, 41 (25%) GPS 1 and 8 (4%) GPS 2. Mean GPS was 0.3 (0–2). 5-year OS was higher in patients with normal CRP than in those with increased CRP (68% vs. 39%; p = 0.007). 5-year OS in patients with GPS 0 and GPS 1 and 2 were 65% and 31% (p = 0.001). 5-year OS for the whole cohort was 56% (1 year: 83%, 3 years: 64%). Recurrence rate was 16.1% closely associated with GPS (p = 0.002). Median follow-up was 23 months (0–118 months). In multivariate analysis GPS, lymph node involvement, T stage and tumor histology were the independent prognostic parameters (p = 0.004, <0.001, 0.035, 0.010). Conclusions Preoperatively increased GPS is significantly associated with reduced postoperative survival and tumor recurrence. The GPS as an independent prognosticator should be interpreted together with the TNM stage when the further postoperative treatment has to be scheduled.</description><identifier>ISSN: 0748-7983</identifier><identifier>EISSN: 1532-2157</identifier><identifier>DOI: 10.1016/j.ejso.2016.10.015</identifier><identifier>PMID: 27839896</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Adenocarcinoma - metabolism ; Adenocarcinoma - mortality ; Adenocarcinoma - pathology ; Adenocarcinoma - surgery ; Adult ; Aged ; Aged, 80 and over ; Biomarkers, Tumor - metabolism ; C-reactive protein ; C-Reactive Protein - metabolism ; Carcinoma, Squamous Cell - metabolism ; Carcinoma, Squamous Cell - mortality ; Carcinoma, Squamous Cell - pathology ; Carcinoma, Squamous Cell - surgery ; Esophageal cancer ; Esophageal Neoplasms - metabolism ; Esophageal Neoplasms - mortality ; Esophageal Neoplasms - pathology ; Esophageal Neoplasms - surgery ; Esophagectomy ; Female ; Glasgow Prognostic Score ; Hematology, Oncology and Palliative Medicine ; Humans ; Male ; Middle Aged ; Neoplasm Recurrence, Local ; Neoplasm Staging ; Predictive Value of Tests ; Prognosis ; Retrospective Studies ; Serum Albumin - metabolism ; Surgery ; Survival ; Survival Rate ; Treatment Outcome</subject><ispartof>European journal of surgical oncology, 2017-02, Vol.43 (2), p.445-453</ispartof><rights>Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology</rights><rights>2016 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology</rights><rights>Copyright © 2016 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c411t-9558706f171a7988de3cf6311fa9968a591bca94fbbd849fc96231ede6353c303</citedby><cites>FETCH-LOGICAL-c411t-9558706f171a7988de3cf6311fa9968a591bca94fbbd849fc96231ede6353c303</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ejso.2016.10.015$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27839896$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lindenmann, J</creatorcontrib><creatorcontrib>Fink-Neuboeck, N</creatorcontrib><creatorcontrib>Avian, A</creatorcontrib><creatorcontrib>Pichler, M</creatorcontrib><creatorcontrib>Habitzruther, M</creatorcontrib><creatorcontrib>Maier, A</creatorcontrib><creatorcontrib>Smolle-Juettner, F.M</creatorcontrib><title>Preoperative Glasgow Prognostic Score as additional independent prognostic parameter for patients with esophageal cancer after curative esophagectomy</title><title>European journal of surgical oncology</title><addtitle>Eur J Surg Oncol</addtitle><description>Abstract Background Inflammation accelerates tumor growth followed by reduced survival in patients with cancer. The aim of this study was to evaluate the prognostic relevance of preoperatively increased levels of C-reactive protein (CRP) and the corresponding Glasgow Prognostic Score (GPS) on patients with esophageal carcinoma undergoing curative esophagectomy. Methods The data of 174 operated esophageal cancer patients were evaluated retrospectively. Patient's demographic and clinico-pathological data, tumor specific data, preoperative plasma levels of CRP and albumin, the corresponding GPS, overall survival (OS) and progression free survival (PFS) were assessed. Results 103 (59.2%) had adenocarcinoma and 71 (40.8%) had squamous cell carcinoma. 71 patients (43%) had elevated CRP concentrations. 118 patients (71%) had GPS 0, 41 (25%) GPS 1 and 8 (4%) GPS 2. Mean GPS was 0.3 (0–2). 5-year OS was higher in patients with normal CRP than in those with increased CRP (68% vs. 39%; p = 0.007). 5-year OS in patients with GPS 0 and GPS 1 and 2 were 65% and 31% (p = 0.001). 5-year OS for the whole cohort was 56% (1 year: 83%, 3 years: 64%). Recurrence rate was 16.1% closely associated with GPS (p = 0.002). Median follow-up was 23 months (0–118 months). In multivariate analysis GPS, lymph node involvement, T stage and tumor histology were the independent prognostic parameters (p = 0.004, <0.001, 0.035, 0.010). Conclusions Preoperatively increased GPS is significantly associated with reduced postoperative survival and tumor recurrence. The GPS as an independent prognosticator should be interpreted together with the TNM stage when the further postoperative treatment has to be scheduled.</description><subject>Adenocarcinoma - metabolism</subject><subject>Adenocarcinoma - mortality</subject><subject>Adenocarcinoma - pathology</subject><subject>Adenocarcinoma - surgery</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>C-reactive protein</subject><subject>C-Reactive Protein - metabolism</subject><subject>Carcinoma, Squamous Cell - metabolism</subject><subject>Carcinoma, Squamous Cell - mortality</subject><subject>Carcinoma, Squamous Cell - pathology</subject><subject>Carcinoma, Squamous Cell - surgery</subject><subject>Esophageal cancer</subject><subject>Esophageal Neoplasms - metabolism</subject><subject>Esophageal Neoplasms - mortality</subject><subject>Esophageal Neoplasms - pathology</subject><subject>Esophageal Neoplasms - surgery</subject><subject>Esophagectomy</subject><subject>Female</subject><subject>Glasgow Prognostic Score</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local</subject><subject>Neoplasm Staging</subject><subject>Predictive Value of Tests</subject><subject>Prognosis</subject><subject>Retrospective Studies</subject><subject>Serum Albumin - metabolism</subject><subject>Surgery</subject><subject>Survival</subject><subject>Survival Rate</subject><subject>Treatment Outcome</subject><issn>0748-7983</issn><issn>1532-2157</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9ksuKFDEUhoMoTjv6Ai4kSzfV5lK3gAgyjKMw4MDoOqSTUz0pqyplkpqhH8T39RTdo-DCTS6H7z_hP38Iec3ZljNev-u30KewFXjGwpbx6gnZ8EqKQvCqeUo2rCnbolGtPCMvUuoZY0o26jk5E00rVavqDfl1EyHMEE3290CvBpP24YHexLCfQsre0lsbIlCTqHHOZx8mM1A_OZgBlynT-S86m2hGyBBpFyLeskcg0Qef7yikMN-ZPaDamskiY7qVtMvp6UfA5jAeXpJnnRkSvDrt5-T7p8tvF5-L669XXy4-Xhe25DwXqqrahtUdb7hBm60Dabtact4ZperWVIrvrFFlt9u5tlSdVbWQHBzUspJWMnlO3h77ooufC6SsR58sDIOZICxJcxwT50IJgag4ojaGlCJ0eo5-NPGgOdNrHLrXaxx6jWOtYRwoenPqv-xGcH8kj_NH4P0RAHR57yHqZHFqFpyPOArtgv9__w__yO3gJ2_N8AMOkPqwRMwLfegkNNO364dY_wOvJVNVWcrfGuy1Aw</recordid><startdate>20170201</startdate><enddate>20170201</enddate><creator>Lindenmann, J</creator><creator>Fink-Neuboeck, N</creator><creator>Avian, A</creator><creator>Pichler, M</creator><creator>Habitzruther, M</creator><creator>Maier, A</creator><creator>Smolle-Juettner, F.M</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20170201</creationdate><title>Preoperative Glasgow Prognostic Score as additional independent prognostic parameter for patients with esophageal cancer after curative esophagectomy</title><author>Lindenmann, J ; Fink-Neuboeck, N ; Avian, A ; Pichler, M ; Habitzruther, M ; Maier, A ; Smolle-Juettner, F.M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c411t-9558706f171a7988de3cf6311fa9968a591bca94fbbd849fc96231ede6353c303</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adenocarcinoma - metabolism</topic><topic>Adenocarcinoma - mortality</topic><topic>Adenocarcinoma - pathology</topic><topic>Adenocarcinoma - surgery</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>C-reactive protein</topic><topic>C-Reactive Protein - metabolism</topic><topic>Carcinoma, Squamous Cell - metabolism</topic><topic>Carcinoma, Squamous Cell - mortality</topic><topic>Carcinoma, Squamous Cell - pathology</topic><topic>Carcinoma, Squamous Cell - surgery</topic><topic>Esophageal cancer</topic><topic>Esophageal Neoplasms - metabolism</topic><topic>Esophageal Neoplasms - mortality</topic><topic>Esophageal Neoplasms - pathology</topic><topic>Esophageal Neoplasms - surgery</topic><topic>Esophagectomy</topic><topic>Female</topic><topic>Glasgow Prognostic Score</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local</topic><topic>Neoplasm Staging</topic><topic>Predictive Value of Tests</topic><topic>Prognosis</topic><topic>Retrospective Studies</topic><topic>Serum Albumin - metabolism</topic><topic>Surgery</topic><topic>Survival</topic><topic>Survival Rate</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lindenmann, J</creatorcontrib><creatorcontrib>Fink-Neuboeck, N</creatorcontrib><creatorcontrib>Avian, A</creatorcontrib><creatorcontrib>Pichler, M</creatorcontrib><creatorcontrib>Habitzruther, M</creatorcontrib><creatorcontrib>Maier, A</creatorcontrib><creatorcontrib>Smolle-Juettner, F.M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of surgical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lindenmann, J</au><au>Fink-Neuboeck, N</au><au>Avian, A</au><au>Pichler, M</au><au>Habitzruther, M</au><au>Maier, A</au><au>Smolle-Juettner, F.M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Preoperative Glasgow Prognostic Score as additional independent prognostic parameter for patients with esophageal cancer after curative esophagectomy</atitle><jtitle>European journal of surgical oncology</jtitle><addtitle>Eur J Surg Oncol</addtitle><date>2017-02-01</date><risdate>2017</risdate><volume>43</volume><issue>2</issue><spage>445</spage><epage>453</epage><pages>445-453</pages><issn>0748-7983</issn><eissn>1532-2157</eissn><abstract>Abstract Background Inflammation accelerates tumor growth followed by reduced survival in patients with cancer. The aim of this study was to evaluate the prognostic relevance of preoperatively increased levels of C-reactive protein (CRP) and the corresponding Glasgow Prognostic Score (GPS) on patients with esophageal carcinoma undergoing curative esophagectomy. Methods The data of 174 operated esophageal cancer patients were evaluated retrospectively. Patient's demographic and clinico-pathological data, tumor specific data, preoperative plasma levels of CRP and albumin, the corresponding GPS, overall survival (OS) and progression free survival (PFS) were assessed. Results 103 (59.2%) had adenocarcinoma and 71 (40.8%) had squamous cell carcinoma. 71 patients (43%) had elevated CRP concentrations. 118 patients (71%) had GPS 0, 41 (25%) GPS 1 and 8 (4%) GPS 2. Mean GPS was 0.3 (0–2). 5-year OS was higher in patients with normal CRP than in those with increased CRP (68% vs. 39%; p = 0.007). 5-year OS in patients with GPS 0 and GPS 1 and 2 were 65% and 31% (p = 0.001). 5-year OS for the whole cohort was 56% (1 year: 83%, 3 years: 64%). Recurrence rate was 16.1% closely associated with GPS (p = 0.002). Median follow-up was 23 months (0–118 months). In multivariate analysis GPS, lymph node involvement, T stage and tumor histology were the independent prognostic parameters (p = 0.004, <0.001, 0.035, 0.010). Conclusions Preoperatively increased GPS is significantly associated with reduced postoperative survival and tumor recurrence. The GPS as an independent prognosticator should be interpreted together with the TNM stage when the further postoperative treatment has to be scheduled.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>27839896</pmid><doi>10.1016/j.ejso.2016.10.015</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0748-7983 |
| ispartof | European journal of surgical oncology, 2017-02, Vol.43 (2), p.445-453 |
| issn | 0748-7983 1532-2157 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1839112922 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Adenocarcinoma - metabolism Adenocarcinoma - mortality Adenocarcinoma - pathology Adenocarcinoma - surgery Adult Aged Aged, 80 and over Biomarkers, Tumor - metabolism C-reactive protein C-Reactive Protein - metabolism Carcinoma, Squamous Cell - metabolism Carcinoma, Squamous Cell - mortality Carcinoma, Squamous Cell - pathology Carcinoma, Squamous Cell - surgery Esophageal cancer Esophageal Neoplasms - metabolism Esophageal Neoplasms - mortality Esophageal Neoplasms - pathology Esophageal Neoplasms - surgery Esophagectomy Female Glasgow Prognostic Score Hematology, Oncology and Palliative Medicine Humans Male Middle Aged Neoplasm Recurrence, Local Neoplasm Staging Predictive Value of Tests Prognosis Retrospective Studies Serum Albumin - metabolism Surgery Survival Survival Rate Treatment Outcome |
| title | Preoperative Glasgow Prognostic Score as additional independent prognostic parameter for patients with esophageal cancer after curative esophagectomy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T16%3A27%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Preoperative%20Glasgow%20Prognostic%20Score%20as%20additional%20independent%20prognostic%20parameter%20for%20patients%20with%20esophageal%20cancer%20after%20curative%20esophagectomy&rft.jtitle=European%20journal%20of%20surgical%20oncology&rft.au=Lindenmann,%20J&rft.date=2017-02-01&rft.volume=43&rft.issue=2&rft.spage=445&rft.epage=453&rft.pages=445-453&rft.issn=0748-7983&rft.eissn=1532-2157&rft_id=info:doi/10.1016/j.ejso.2016.10.015&rft_dat=%3Cproquest_cross%3E1839112922%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1839112922&rft_id=info:pmid/27839896&rft_els_id=S0748798316309544&rfr_iscdi=true |